Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 + Ezetimibe 10 Fixed-Dose Combination Compared to Ezetimibe and Placebo In Subjects With T2DM and Elevated LDL-Cholesterol

Trial Profile

A Randomized Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 + Ezetimibe 10 Fixed-Dose Combination Compared to Ezetimibe and Placebo In Subjects With T2DM and Elevated LDL-Cholesterol

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bempedoic acid/ezetimibe (Primary) ; Ezetimibe
  • Indications Hypercholesterolaemia; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Esperion Therapeutics

Most Recent Events

  • 30 Mar 2020 Results (n=179) presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology
  • 30 Mar 2020 Results presented in a Daiichi Sankyo Europe media release.
  • 28 Mar 2020 According to a Esperion AB media release, results from this trial were presented at the at the American College of Cardiology's 69th Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) on March 28th-30th 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top